Abstract
With the goal to achieve highly efficacious MRI-monitored magnetic targeting, a novel drug carrier with dual nature of superior magnetophoretic mobility and superparamagnetism was synthesized. This carrier was specially designed in a core-shell structure. The core was achieved by utilizing a strategy of self-assembly of oppositely charged ultrafine superparamagnetic iron oxide nanoparticles previously prepared. The final particles were formed by coating such cores with carboxymethyldextran (CMD) polymer. By exclusion of non-magnetic materials from the interior part of the particles, this structure maximized the amount of magnetic material and thus yielded a superior magnetophoretic mobility. Such a strategy avoids the challenge of superparamagnetism loss, which would be caused by cores exceeding a critical domain size. Coating the self-assembled core enables the magnetic carrier to be stable upon usage and storage and to be readily linked with drug molecules for therapeutic applications. In vitro characterization showed that these nanoparticles displayed a 3- to 4-fold enhancement in magnetophoretic mobility, and a markedly improved stability when stored in 50% serum as a comparison of conventional iron oxide-based magnetic nanoparticles. Preliminary in vivo studies revealed that the nanoparticles also function well as a contrast enhancer for MR imaging of brain glioma. This technology could lead to the development of a new paradigm of magnetic carriers that meet with the needs of various clinical applications.